Cerliponase alfa - Biologic Drug Details

Summary for cerliponase alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for cerliponase alfa

Recent Clinical Trials for cerliponase alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
David L Rogers, MD	Phase 1/Phase 2

See all cerliponase alfa clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for cerliponase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for cerliponase alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	BRINEURA	cerliponase alfa	Injection	761052		2026-08-22	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	BRINEURA	cerliponase alfa	Injection	761052		2030-09-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for cerliponase alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for cerliponase alfa

Country	Patent Number	Estimated Expiration
Canada	2408380
Mexico	PA02011162
Australia	6308501
Austria	E360438
European Patent Office	1292326
World Intellectual Property Organization (WIPO)	0185200

Market Dynamics and Financial Trajectory for Cerliponase Alfa

Last updated: February 20, 2026

What Is Cerliponase Alfa and Its Approved Use?

Cerliponase alfa is a recombinant human enzyme indicated for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a rare neurodegenerative lysosomal storage disorder. It mimics the deficient enzyme tripeptidyl peptidase 1 (TPP1) and is administered via intraventricular infusion directly into the brain. Developed by Apellis Pharmaceuticals, licensed to BioMarin Pharmaceutical for commercialization, it received FDA approval in June 2017.

How Large Is the Market for Cerliponase Alfa?

The global market for orphan drugs targeting rare neurodegenerative conditions like CLN2 is projected to grow steadily. Key factors include:

• Prevalence: CLN2 disease affects approximately 1 in 100,000 to 1 in 200,000 newborns. Estimated total patient population in developed markets ranges between 300 and 500 individuals.
• Pricing: The list price for cerliponase alfa in the U.S. is approximately $702,000 annually per patient (per dosing regimen of 300 mg every 14 days).[1]
• Market Penetration: Currently, fewer than 50 patients in the U.S. are treated annually due to diagnosis challenges, broad geographic distribution, and the high cost.

What Are the Key Market Drivers?

Growing diagnosis rates and increased awareness

• Improved genetic screening and diagnostic techniques have identified more patients.
• Expansion of newborn screening programs in certain regions could facilitate earlier diagnosis.

Regulatory and commercial prospects

• Major markets such as the U.S., Europe, and Japan have approved the drug, with some extending orphan exclusivity periods.

Competitive landscape

• Limited competition exists, but no other enzyme replacement therapies specifically target CLN2.
• Investigational therapies include gene therapies and other enzyme replacement candidates, potentially impacting long-term market share.

What Are the Main Challenges and Risks?

Patient identification and diagnosis barriers

• Low disease prevalence complicates widespread diagnosis.
• Variability in clinical presentation delays treatment initiation.

High treatment costs and reimbursement hurdles

• Price points around $700,000 annually may limit payer willingness.
• Reimbursement rates vary; insurance coverage is critical for patient access.

Manufacturing complexities

• Intracerebral infusion catheter systems have procedural risks.
• Consistent manufacturing of biologics with complex delivery devices influences supply stability and costs.

Market penetration and access

• Establishing treatment centers equipped for intraventricular infusion affects uptake.
• Geographic inequities remain significant, particularly in emerging markets.

What Are the Financial Trajectories and Revenue Expectations?

Historical revenue data

• BioMarin reported peak sales of cerliponase alfa at approximately $55 million in 2021, representing a modest but steady growth trajectory.[2]
• Revenues are limited by the small patient base; estimates for 2022-2023 suggest a slight increase as diagnosis and treatment rates improve.

Future growth prospects

Factor	Impact	Outlook
Expanding diagnostic coverage	Potential increase in identified patients	Moderate to high
Off-label use or expanded indications	Currently not approved but under investigation	Low, unless new indications are approved
Introduction of gene therapies	Could replace or diminish enzyme replacement sales	Medium to high risk depending on efficacy and approval timelines
Price inflation and reimbursement movement	Could sustain or increase revenue levels	Moderate risk due to payer resistance

Revenue projections comparison

• The therapy’s revenue is expected to grow at a compound annual growth rate (CAGR) of roughly 5-8% over the next five years if diagnosis and access improve.
• Market size expansion hinges on increasing patient identification and adoption, but no significant changes in price points or new indications are anticipated in the near term.

How Does Cerliponase Alfa Fit Into the Broader Orphan and Neurodegenerative Drug Market?

• It belongs to a rapidly evolving niche that includes gene therapies (e.g., AXO-AAV-GM1 for GM1 gangliosidosis) and other enzyme replacement therapies.
• The global orphan drug market is projected to reach $209 billion by 2030, growing at a CAGR of 8%.[3]
• Cerliponase alfa has low competition but faces pressure from investigational programs and potential gene therapy approvals that could impact its long-term financial trajectory.

What Are the Strategic Considerations for Investors and R&D?

• Prioritize companies investing in early diagnosis tools.
• Monitor developments in gene and cell therapies targeting CLN2 and similar neurodegenerative disorders.
• Evaluate pricing strategies and reimbursement negotiations influencing revenue sustainability.
• Consider geographic expansion opportunities, notably in regions with emerging healthcare infrastructure.

Key Takeaways

• Cerliponase alfa is a niche orphan enzyme replacement therapy with a high price point but limited patient access due to rarity and treatment complexity.
• Revenue growth will depend primarily on increased diagnosis, regional expansion, and reimbursement policies.
• Market risks include competition from future gene therapies, treatment access barriers, and manufacturing challenges.
• The therapy's long-term financial footprint remains modest compared to larger orphan indications but is notable within neurodegenerative rare diseases.

FAQs

1. What limits the market size for cerliponase alfa?
Its therapeutic indication covers a rare patient population estimated at fewer than 500 globally, constrained further by diagnostic challenges and treatment access barriers.

2. How is pricing justified for cerliponase alfa?
High treatment costs reflect the rarity of the disease, complex manufacturing, and delivery methods, combined with the clinical data supporting its efficacy.

3. Are there upcoming competitors or alternative therapies?
No direct enzyme replacement competitors currently exist, but gene therapy candidates are under development, potentially disrupting the market.

4. What are reimbursement challenges faced by manufacturers?
Payors often challenge the high cost-to-benefit ratio for extremely rare diseases, leading to variable coverage policies.

5. Could new diagnostic techniques impact the market?
Yes, the expansion of newborn screening and genetic testing can increase diagnosed cases, driving future revenue growth.

---

References

[1] BioMarin Pharmaceutical Inc. (2018). Cerliponase alfa (Brineura) Pricing Details.
[2] BioMarin Annual Report. (2022). Financials and Revenue Data.
[3] Grand View Research. (2022). Global Orphan Drug Market Size & Trends.

Note: All prices and projections are approximate and based on publicly available data from 2022-2023.